Episode 23: A Between the Biotech Waves conversation with Jim Birchenough, Vice Chair of Wells Fargo Biopharmaceutical Inv Banking
Between the Biotech Waves
00:00
Do You Think We've Got a Full Reset of Public Market Valuation?
The class of 2023, as we look at it, is a much healthier class than the class of 2020 and 2021. We've seen a number of these companies execute really well around strategic collaborations to really put themselves in an optimal position of strength. And I think they have things in place that put themPut them in a good position for high-end clearances and,. you know, a quick start on clinical development.
Transcript
Play full episode
